about
Short term micronutrient-antioxidant supplementation has no impact on a serological marker of gastric atrophy in Zambian adults: retrospective analysis of a randomised controlled trial.HIV infection and domestic smoke exposure, but not human papillomavirus, are risk factors for esophageal squamous cell carcinoma in Zambia: a case-control study.Trends in upper gastrointestinal diagnosis over four decades in Lusaka, Zambia: a retrospective analysis of endoscopic findings.Esophageal squamous cell cancer in a highly endemic region.Serological response to Epstein-Barr virus early antigen is associated with gastric cancer and human immunodeficiency virus infection in Zambian adults: a case-control study.Adjuvant potential of low dose all-trans retinoic acid during oral typhoid vaccination in Zambian men.Lumbar puncture refusal in sub-Saharan Africa: A call for further understanding and interventionHigh prevalence of gastric intestinal metaplasia detected by confocal laser endomicroscopy in Zambian adults.Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial.Mycobacterium avium lysate induces matrix metalloproteinase-1 in intestinal tissue and peripheral blood: observations from selected hospital based Zambian adults.A seven-year retrospective review of colonoscopy records from a single centre in Zambia.Presence of blood in gastric juice: A sensitive marker for gastric cancer screening in a poor resource settingThe African Esophageal Cancer Consortium: A Call to ActionCancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening?Molecular profiling of gastric cancer in a population with high HIV prevalence reveals a shift to MLH1 loss but not the EBV subtypeHIV related hypochlorhydria does not appear to respond to anti-retroviral therapy in Zambian adults: a case control study
P50
Q35130622-823908D9-5522-4009-8B0E-21BB2EC6C627Q35469433-ACE39686-9251-492A-B9BE-6D41D4FB1E0CQ36131072-921E573C-D7DD-46C9-B39D-263FF89BC664Q36650819-3D6C0611-59FE-48CA-9505-E9A47931EFADQ36888755-A473E30B-9929-4845-A145-F4B78747E35DQ39182828-9C177BCC-0ED6-4411-88F8-669D7615AB34Q39519314-4023ADF2-D7C7-4F43-8F47-418EE0775A4CQ40060281-87A842C9-9FB3-4CC3-8D1E-535423D4D643Q50048814-019893D8-6DC0-40B6-B708-C0138583442BQ52691636-BEEB669F-E280-4604-B536-23F2B39DB7D4Q55341667-F8196BF5-01E3-491D-9857-5E80A4171C0EQ57465592-32053D00-012D-46B7-A1E6-622841C24EE6Q62488822-92E3C878-4EFB-4542-9963-58DF854D8C1EQ64055565-A157163E-3F8D-4D93-8C51-CF85CE1ADDB1Q90616647-7B169C3D-5FBD-4E5F-964A-F0999E108C27Q91626331-64D76935-473F-41AC-9C55-D58E62CCDD91
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Violet Kayamba
@en
Violet Kayamba
@nl
type
label
Violet Kayamba
@en
Violet Kayamba
@nl
prefLabel
Violet Kayamba
@en
Violet Kayamba
@nl
P31
P496
0000-0002-6521-2501